TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26855980

Group type: EXPERIMENTAL
Intervention: Low-dosage quetiapine (150 mg/d)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Moderate-dosage quetiapine (300 mg/d)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 23016508

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (90 mg gel once daily)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Intramuscular progesterone (250 mg weekly)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 518

Group type: COMPARATOR
Intervention: Intramuscular progesterone
Number of subjects: 518
Study: 21708967

Group type: EXPERIMENTAL
Intervention: Multidisciplinary integrated care
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340
Study: 19440086

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16631923

Group type: EXPERIMENTAL
Intervention: Mechanical cycling (20,000 cycles under 50 N load, immersion in distilled water at 37 degrees C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No mechanical cycling
Number of subjects: 40
Study: 15609842

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 33
Study: 12036265

Group type: EXPERIMENTAL
Intervention: Adaptive two-stage dose-response trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss-function based approach for dose selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive two-stage designs with dose-selection rule
Number of subjects: 0
Study: 10332319

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-cost occlusal appliances
Number of subjects: 0
Study: 8486515

Group type: EXPERIMENTAL
Intervention: Streptomycin (1 g) with 2% lidocaine (3 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine alone (3 ml)
Number of subjects: 20
Study: 2444395

Group type: EXPERIMENTAL
Intervention: Topical glucocorticosteroid (flumethasone pivalate 0.02 percent)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aqueous solution of eosin 2 percent
Number of subjects: 30
Study: 30281180

Group type: COMPARATOR
Intervention: Oral chloral hydrate at 50 mg kg-1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 3 μg kg-1 plus buccal midazolam at 0.1 mg kg-1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine plus buccal midazolam
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 160
Study: 27321983

Group type: EXPERIMENTAL
Intervention: Unconstrained training group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constrained training group
Number of subjects: 0
Study: 25413281

Group type: EXPERIMENTAL
Intervention: Structured rehabilitation after lumbar spine surgery
Number of subjects: 124
Study: 23408867

Group type: EXPERIMENTAL
Intervention: 4 mg/kg octanoic acid (OA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 20395941

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) therapy with losartan
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) therapy with atenolol
Number of subjects: 9193
Study: 19018919

Group type: EXPERIMENTAL
Intervention: Clinical reminder on paper chart
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (no clinical reminder)
Number of subjects: 194
Study: 21055945

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (TDCS) applied to the parietal lobes during numerical learning for 6 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control tasks (not specified in detail).
Number of subjects: 0
Study: 15704099

Group type: EXPERIMENTAL
Intervention: EFL group (40 teeth treated with fluoride gel and lased)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: EF group (40 teeth treated with fluoride gel)
Number of subjects: 98

Group type: COMPARATOR
Intervention: E group (18 teeth untreated control)
Number of subjects: 98
Study: 12417370

Group type: EXPERIMENTAL
Intervention: Galantamine (Reminyl®)
Number of subjects: 0
Study: 9813986

Group type: EXPERIMENTAL
Intervention: Cefixime 10 mg/kg/day orally for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chloramphenicol 50 mg/kg/day orally for 14 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefixime (after switching from chloramphenicol)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefixime overall
Number of subjects: 40
Study: 8071291

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-250 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Clomipramine (100-250 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fluvoxamine and Clomipramine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 66
Study: 3292598

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 20
Study: 11310519

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticlopidine and Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin and extended-release dipyridamole
Number of subjects: 0
Study: 29908236

Group type: EXPERIMENTAL
Intervention: Retaliation against the outgroup during the cold-pressor task
Number of subjects: 0

Group type: COMPARATOR
Intervention: No retaliation against the outgroup during the cold-pressor task
Number of subjects: 0
Study: 27866195

Group type: EXPERIMENTAL
Intervention: Telbivudine (LDT) 600 mg/d
Number of subjects: 130

Group type: COMPARATOR
Intervention: Entecavir (ETV) 0.5 mg/d
Number of subjects: 130
Study: 24746916

Group type: EXPERIMENTAL
Intervention: Exercise therapy plus manual mobilizations
Number of subjects: 34

Group type: COMPARATOR
Intervention: Exercise therapy only
Number of subjects: 34
Study: 23328095

Group type: EXPERIMENTAL
Intervention: MRI navigation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Routine operation without MRI navigation
Number of subjects: 65
Study: 19924412

Group type: EXPERIMENTAL
Intervention: Minimum ADC
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Average ADC
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Post-chemotherapy values
Number of subjects: 22
Study: 18385499

Group type: EXPERIMENTAL
Intervention: Bone mineral density measurements using dual-energy x-ray absorptiometry
Number of subjects: 1
Study: 16113133

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 38
Study: 12466367

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 6.25 micro g/kg sc daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Testosterone (T) transdermal patch 5.0 mg/daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined Hormones (GHT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 10
Study: 10526999

Group type: EXPERIMENTAL
Intervention: ETS exposure at work
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: ETS exposure during leisure time
Number of subjects: 914

Group type: COMPARATOR
Intervention: Unexposed to ETS
Number of subjects: 914
Study: 8773292

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (FX)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Tricyclic Antidepressant (TCA)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 462
Study: 2268639

Group type: EXPERIMENTAL
Intervention: Conservative stomatological treatment with beta-adrenergic blocking agent 'Obsidan'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 0
Study: 85006

Group type: EXPERIMENTAL
Intervention: Chemotherapy as the only treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus local irradiation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Chemotherapy (Doxorubicin‐containing drug regimens)
Number of subjects: 22
Study: 30722657

Group type: EXPERIMENTAL
Intervention: Repeated-sprint training in hypoxia (RSH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Repeated-sprint training in normoxia (RSN)
Number of subjects: 12
Study: 29951742

Group type: EXPERIMENTAL
Intervention: Abaloparatide (ABL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study: 26606200

Group type: EXPERIMENTAL
Intervention: 74-Gy radiation therapy (RT) with concurrent and consolidation carboplatin/paclitaxel
Number of subjects: 313

Group type: COMPARATOR
Intervention: 60-Gy radiation therapy (RT) with concurrent and consolidation carboplatin/paclitaxel
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Intensity-modulated RT (IMRT)
Number of subjects: 313

Group type: COMPARATOR
Intervention: 3-dimensional conformal RT (3D-CRT)
Number of subjects: 313
Study: 25177682

Group type: EXPERIMENTAL
Intervention: 6-hour EDD sessions
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 10-hour EDD sessions
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 75
Study: 23534328

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, Minocycline, Metronidazole
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, Tinidazole, Minocycline
Number of subjects: 25
Study: 20710094

Group type: EXPERIMENTAL
Intervention: Neuromuscular training program (NMTP) for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no NMTP) for 8 weeks
Number of subjects: 20
Study: 17685720

Group type: EXPERIMENTAL
Intervention: Protease supplement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 20
Study: 15807275

Group type: EXPERIMENTAL
Intervention: haiguiyuyang capsule
Number of subjects: 438

Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 438
Study: 12072673

Group type: EXPERIMENTAL
Intervention: Propofol (PL)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ketamine with midazolam and fentanyl (KMF)
Number of subjects: 98
Study: 11792284

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg/h)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Remifentanil (3 microgram/kg/h)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 9676901

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine (stage one)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine (stage two)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No caffeine (stage one)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No caffeine (stage two)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine at breakfast
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine in fruit-juice (for subjects who had not had caffeine at breakfast)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Caffeine in stage one and stage two
Number of subjects: 36
Study: 8141101

Group type: COMPARATOR
Intervention: Ftorafur, 400 mg/m2/day (Group A)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Ftorafur, 400 mg/m2/day and Tamoxifen, 20 mg/day (Group B)
Number of subjects: 554
Study: 3051673

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg twice a day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate (4 mg four times a day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined acetazolamide and dexamethasone therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 4938243

Group type: EXPERIMENTAL
Intervention: Baclofen (Lioresal)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31937238

Group type: EXPERIMENTAL
Intervention: Flexible reinforced laryngeal mask airway (FLMA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 96
Study: 31389723

Group type: EXPERIMENTAL
Intervention: Special intervention group
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 12866

Group type: EXPERIMENTAL
Intervention: 11-event composite
Number of subjects: 12866
Study: 28545491

Group type: EXPERIMENTAL
Intervention: TESI plus Levobupivacaine added to oral pain medication
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Transforaminal epidural injection (TEI) with Levobupivacaine and saline solution added to oral pain medication
Number of subjects: 264

Group type: COMPARATOR
Intervention: Oral pain medication
Number of subjects: 264
Study: 26408391

Group type: EXPERIMENTAL
Intervention: 3D volumetric models obtained from Cone Beam Computer Tomography (CBCT)
Number of subjects: 23
Study: 23570446

Group type: EXPERIMENTAL
Intervention: Purified formula of almond and olive oil, enriched with vitamin B1, B2, B6, E and fatty acids
Number of subjects: 164

Group type: COMPARATOR
Intervention: Liquid wax (jojoba oil)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both oils (almond/olive oil and jojoba oil)
Number of subjects: 164
Study: 21434843

Group type: EXPERIMENTAL
Intervention: Bifrontotemporoparietal decompressive craniectomy
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 155
Study: 19936527

Group type: EXPERIMENTAL
Intervention: PA + AS (35% phosphoric acid gel + adhesive system)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PA + 10% NaOCl + AS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PA + oxalate + AS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PA + oxalate + 10% NaOCl + AS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxalic acid alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% NaOCl alone or in combination with oxalic acid
Number of subjects: 0
Study: 17014560

Group type: EXPERIMENTAL
Intervention: Combined low-dose tacrolimus (2 mg/day) and prednisone (30 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prednisone (1 mg/kg per day)
Number of subjects: 60
Study: 15232796

Group type: EXPERIMENTAL
Intervention: Calcium diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcium supplement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L‐glutamine supplement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L‐cystine supplement
Number of subjects: 20
Study: 11781679

Group type: COMPARATOR
Intervention: Glucose (G), n=71
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Glucose-fructose-xylitol 2:1:1 (GFX), n=67
Number of subjects: 138
Study: 9577049

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8465162

Group type: EXPERIMENTAL
Intervention: Unicompartmental Brigham knee prosthesis
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High tibial osteotomy
Number of subjects: 59
Study: 3802729

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally every six hours, beginning two days before lidocaine administration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cimetidine hydrochloride 300 mg i.v. every six hours, beginning one hour before lidocaine administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo tablet every six hours, beginning two days before lidocaine administration
Number of subjects: 6
Study: 31058534

Group type: EXPERIMENTAL
Intervention: Overexpression of NBPF1 gene in A431 cell line via plasmid transfection
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 1
Study: 29203583

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study: 27501015

Group type: EXPERIMENTAL
Intervention: Pudendal block (0.25% bupivacaine 0.5 mL/kg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pudendal block
Number of subjects: 84

Group type: COMPARATOR
Intervention: Caudal block (0.2% bupivacaine 1 mL/kg)
Number of subjects: 84
Study: 24316514

Group type: EXPERIMENTAL
Intervention: Serelaxin (30 μg/kg/day for 48 hours)
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1161
Study: 22270738

Group type: EXPERIMENTAL
Intervention: Local anesthetic only
Number of subjects: 120

Group type: COMPARATOR
Intervention: Local anesthetic combined with nonparticulate betamethasone
Number of subjects: 120
Study: 19737595

Group type: EXPERIMENTAL
Intervention: 15% hydrochloric acid gel (HCl) for 120s
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid gel (H(3)PO(4)) for 120s
Number of subjects: 32
Study: 17712577

Group type: EXPERIMENTAL
Intervention: Unilateral laminectomy (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unilateral laminotomy (Group 2)
Number of subjects: 100
Study: 15832060

Group type: EXPERIMENTAL
Intervention: Automated labeling pathway (ALP)
Number of subjects: 28
Study: 12844393

Group type: EXPERIMENTAL
Intervention: Enterostatin (ENT) 3 x 15 mg/d
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enterostatin (ENT)
Number of subjects: 12
Study: 10634196

Group type: EXPERIMENTAL
Intervention: Alferon LDO
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Veldona
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Ferimmune
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 9166485

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (150 U/kg), subcutaneously, three times a week for 3 months
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo, subcutaneously, three times a week for 3 months
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: r‐HuEPO
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 1718477

Group type: EXPERIMENTAL
Intervention: Morphine, 1 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxymorphone, 0.2 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl, 50 micrograms/kg
Number of subjects: 30
Study: 7081040

Group type: EXPERIMENTAL
Intervention: Dobutamine (DBM) at 5 micrograms/kg/min
Number of subjects: 13

Group type: COMPARATOR
Intervention: Dopamine (DPM) at 5 micrograms/kg/min
Number of subjects: 13

Group type: COMPARATOR
Intervention: Dopamine (DPM) at 10 micrograms/kg/min
Number of subjects: 13
Study: 3840189

Group type: EXPERIMENTAL
Intervention: UVB-induced tan
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: UVA-induced tan
Number of subjects: 5
Study: 28918108

Group type: EXPERIMENTAL
Intervention: HFrecEF
Number of subjects: 318

Group type: COMPARATOR
Intervention: HFrEF
Number of subjects: 318
Study: 28243296

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 24794475

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 173

Group type: COMPARATOR
Intervention: Non-statin users
Number of subjects: 173
Study: 23018655

Group type: EXPERIMENTAL
Intervention: etafilcon A lenses
Number of subjects: 30
Study: 20421333

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 18775846

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET; 1 mg/day for 6 months)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (n=9)
Number of subjects: 18
Study: 15677607

Group type: EXPERIMENTAL
Intervention: ondansetron (16 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 11802285

Group type: EXPERIMENTAL
Intervention: Educational program (workshop including crisis management, use of inhaled medication, flow‐metry, and relaxation techniques)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 76
Study: 9751674

Group type: EXPERIMENTAL
Intervention: Xemilofiban 20 mg
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Xemilofiban 15 mg
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo with ticlopidine 250 mg
Number of subjects: 549
Study: 7849747

Group type: EXPERIMENTAL
Intervention: Low-tech exercise
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: High-tech exercise
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control
Number of subjects: 250
Study: 2904751

Group type: EXPERIMENTAL
Intervention: Doxazosin monotherapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Doxazosin combined with beta-blocker
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall doxazosin therapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Doxazosin therapy
Number of subjects: 24
Study: 31714444

Group type: EXPERIMENTAL
Intervention: Psychological intervention during different stages of the operation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 100
Study: 30419956

Group type: EXPERIMENTAL
Intervention: Dyadic planning intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual planning condition
Number of subjects: 0
Study: 26553313

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day for 52 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo for 52 weeks
Number of subjects: 74
Study: 24853083

Group type: EXPERIMENTAL
Intervention: Baseline Q-wave width ≥40ms for inferior MI
Number of subjects: 3589

Group type: EXPERIMENTAL
Intervention: Baseline Q-wave width ≥20ms for lateral/apical MI
Number of subjects: 3589

Group type: EXPERIMENTAL
Intervention: Baseline Q-wave width
Number of subjects: 3589
Study: 22071380

Group type: EXPERIMENTAL
Intervention: VDD pacing (n=166)
Number of subjects: 420

Group type: COMPARATOR
Intervention: DDD pacing (n=254)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 420
Study: 20456062

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine plus 0.2 microg.kg(‐1) of fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine plus 0.9% NaCl (placebo)
Number of subjects: 50